Changing of the guard at NICE

When Andrew Dillon steps down as NICE's chief executive in March 2020, his successor will be tasked with leading an agency that faces an increasingly complex and fast-moving medicines landscape.

The U.K. agency is already going through a period of change after 20 years under Dillon's leadership. Much of that evolution will involve adapting NICE's health technology appraisal methodology to enable patient access to medicines that while highly efficacious are expensive and reach the market with limited evidence. ...